For a year before an osteosarcoma was found in her right proximal tibia, Sammy Ulloa, pushing through pain, persisted with her training as a Division I track and field and cross-country competitor.
After the Plenary: Don Berry: In NeoALTTO & ALTTO Trials, Neoadjuvant Response Predicts Adjuvant
Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
YOU MAY BE INTERESTED IN
Nov. 6, 2023, was a bad day for Tom Curran, a charming scientist with a lilting Scottish brogue and the lifelong dream of curing childhood cancers.
Credit: OHSU/Christine Torres HicksAfter a year as director of the Oregon Health and Science University’s Knight Cancer Institute, Tom Sellers has stepped down from his position. He is replaced by Lisa Coussens, chair of the Department of Cell, Developmental & Cancer Biology, who was appointed interim center director.
In an effort to target the right patients, genetic screening is becoming more common in clinical trials. But incorporating it can be complex and add a significant burden for both patients and clinical trial sites. Genetic counseling can streamline that process and help drug and gene therapy developers expedite the recruitment of genetically-eligible participants for their trials and use genetic testing results to accelerate the speed and success of clinical trials.
Thomas B. Tomasi Jr., who led Roswell Park Comprehensive Cancer Center as president and CEO from 1986 to 1996, died March 23 at age 97. His tenure marked a renaissance at Roswell Park that elevated it to a place among the nation’s top cancer centers.
Dr. Thomas B. Tomasi, Jr. president and CEO of Roswell Park Comprehensive Cancer Center from 1986 to 1996, died on March 23. He was 97.
